GammaTile

More dose,
where you want it,
when you need it

Layer
Layer
Layer

Immediate

Implanted directly into the tumor cavity at the time of resection, GammaTile® initiates radiation therapy when you need it – at the point of lowest tumor burden.

  • Eliminates the delay required for post-operative wound healing before starting conventional radiation therapies.1
  • Targets the tumor site when the tumor burden is at its lowest, minimizing the risk of tumor progression/recurrence during the traditional treatment gap.1-9
  • Provides a single-procedure solution for tumor resection and radiation therapy, reducing patient burden, and ensuring 100% compliance.1

Targeted

Provides highly localized radiation therapy, precisely where you want it.10

  • Minimizes radiation exposure to healthy brain tissue, by delivering radiation dose precisely where needed.10
  • Ideal for hard-to-treat rapidly growing or previously irradiated tumors, ensuring the maximum dose reaches the tumor bed.2,3,6
  • Reduces EBRT side effects such as hair loss.1

Controlled

Efficiently delivers more dose with uniform source distribution, for advanced tumor control.3-10

  • Designed to deliver more dose at the source, without passing through healthy brain tissue.1
  • Cs-131 seeds with a half-life of 9.7 days ensure the planned dose is given in a shorter period at a higher initial dose rate.11
  • Uses collagen tiles as a seed carrier and 3D spacer for uniform source distribution.11

Addressing unmet needs
in brain tumor treatment

Despite technological advances made in EBRT; SRT, IMRT and proton therapy – local control (LC) remains a challenge in the postoperative setting for brain tumors.2,5,6,12-16

Newly Dx Operable Tumors
GBM
Median PFSMedian OS
STANDARD OF CARE~6-8 mos13~15-17 mos13
Newly Dx Operable Tumors
Brain Mets
LC (1-Year)
STANDARD OF CARE60-93%*17-22
Newly Dx Operable Tumors
GBMBrain Mets
Median PFSMedian OSLC (1-Year)
STANDARD OF CARE~6-8 mos13~15-17 mos1360-93%*17-22

PFS = Progression-Free Survival
, OS = Overall Survival
, LC = Local Control

* Rates include resection + WBRT, resection + SRS, and resection + WBRT + SRS boost

...tumor recurrence remains
a primary treatment concern

Additional treatment
challenges of
recurrent tumors

Normal brain tissue has often received high doses of radiation during previous EBRT treatments.4,8,9,11

  • Adjuvant EBRT is often not utilized or underdosed in this population.4,8,9,11
  • Tumor resistance reduces effectiveness and safety of additional EBRT therapy.4,8,9,11

Additional EBRT carries a significant risk of increased radiotoxicity, diminished quality of life, and more financial burden.4,8,9,13

There is no universally defined standard of care for recurrent brain tumors.4,8,9

GammaTile offers increased
local control for your patients with
previously-irradiated brain tumors

Previously-Irradiated Brain Tumors
GBM
Median PFSMedian OS
GammaTile8.2-11.7 mos7,824.4-25.0 mos7,8
Previously-Irradiated Brain Tumors
Brain MetsMenin-
gioma
LC (1-Year)Median OS
GammaTile80-100%2,4,526 mos.9
Previously-Irradiated Brain Tumors
GBMBrain MetsMeningioma
Median PFSMedian OSLC (1-Year)Median OS
GammaTile8.2-11.7 mos7,824.4-25.0 mos7,880-100%2,4,526 mos.9

PFS = Progression-Free Survival
, OS = Overall Survival
, LC = Local Control

Toxicity (Previously-Irradiated Brain Tumors)

0-16% Symptomatic radiation necrosis.2,4,5,7,8

0% Reoperation rate due to GammaTile-related radiation necrosis reported in peer-reviewed publications.2,4,5,7,8

CLINICAL EVIDENCE

The GammaTile Commitment Pledge
for recurrent brain tumors

If a GammaTile treatment of a recurrent brain tumor is canceled because intraoperative pathology reveals only necrotic tissue, we will update the invoice to reflect a $0 charge.*

CONTACT USORDER NOW
* Per the GammaTile Commitment Product Policy, effective December 31, 2023. A purchase order must be submitted for the original order and the customer must not have any past due invoices with GT Medical Technologies. Additional Terms and Conditions apply. Please contact Customer Service for complete policy details.

REFERENCE: 1. Gessler DJ, et al. Future Oncol. 16(30):2445-2455 (2020). 2. Kutuk T, et al. Brachytherapy. 22(6):872-881 (2023). 3. Dharnipragada R, et al. Neurooncol Adv. 5(1):vdad062 (2023). 4. Imber BS, et al. J Neurooncol. 159(3):609-618 (2022). 5. Nakaji P, et al. Cureus. 12(11):e11570 (2020). 6. Yekula A, et al. J Neurooncol. 66(3):441-450 (2024). 7. Gessler DJ, et al. Neurooncol Adv. 4(1):1-11 (2022). 8. Smith N, et al. Neuro Oncol. 24(S6):S4-S15 (2022). 9. Brachman DG, et al. J Neurosurg. 131(6):1819-1828 (2018). 10. Kutuk T, et al. Brachytherapy. 23(6):751-760 (2024). 11. Garcia MA, et al. J Neurooncol. 166:203-212 (2024). 12. Waqar M, et al. Neurooncol Adv. 4(1):1-10 (2022). 13. Stupp R, et al. JAMA. 318(23):2306-2316 (2017). 14. ASTRO Clinical Practice Guideline (2022). 15. Xiong Z, et al. Lancet. 100:104963 (2024). 16. Rogers CL et al. Int J Radiat Oncol Biol Phys. 106(4):790-799 (2020). 17. Mahajan A, et al. Lancet Oncol. 18(8):1040-1048 (2018). 18. Ahmed Z, et al. CNS Oncol. 3(3):199-207 (2014). 19. Quigley MR, et al. Neurosurg. 76(6):707-713 (2015). 20. Patchell RA, et al. JAMA. 280(17):1485-1489 (1998). 21. Baykara M, et al. J Cancer Research and Therapeutics. 10(4):915-921 (2014). 22. Rades D, et al. Clin Neuro and Neurosurg. 114(4):326-330 (2012).
MKT-477-01